Cargando…

CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.

The serum expression of a novel tumour marker, CA 242, defined by monoclonal antibody C 242, was studied in 179 patients with pancreatic cancer. The results were compared with CA 19-9, CA 50 and CEA. CA 242 is a carbohydrate closely related, but not identical, to CA 19-9 and CA 50. The overall sensi...

Descripción completa

Detalles Bibliográficos
Autores principales: Haglund, C., Lundin, J., Kuusela, P., Roberts, P. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033366/
https://www.ncbi.nlm.nih.gov/pubmed/8080735
_version_ 1782136822506192896
author Haglund, C.
Lundin, J.
Kuusela, P.
Roberts, P. J.
author_facet Haglund, C.
Lundin, J.
Kuusela, P.
Roberts, P. J.
author_sort Haglund, C.
collection PubMed
description The serum expression of a novel tumour marker, CA 242, defined by monoclonal antibody C 242, was studied in 179 patients with pancreatic cancer. The results were compared with CA 19-9, CA 50 and CEA. CA 242 is a carbohydrate closely related, but not identical, to CA 19-9 and CA 50. The overall sensitivity of the CA 242 assay was 74%: 55% in stage I, 83% in stage II-III and 78% in stage IV disease. The specificity calculated from 112 patients with benign diseases was 91%. CA 19-9 had a higher sensitivity of 83%, but the specificity was only 81%. When comparing the markers by receiver operating characteristic analysis, the sensitivities were almost identical at all specificity levels. The CA 242 level was elevated in 7%, 15% and 7% of patients with benign pancreatic, biliary and liver disease respectively. The corresponding figures for CA 19-9 were 19%, 28% and 15% respectively. The sensitivity of CA 242 was higher than that of CA 50 and CEA at all specificity levels. In conclusion, tumour marker CA 242 seems to be a useful diagnostic tool for the diagnosis of pancreatic cancer, and is an alternative to CA 19-9. The advantage of CA 242 over CA 19-9 is its higher specificity when using the recommended cut-off levels of the assays.
format Text
id pubmed-2033366
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20333662009-09-10 CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Haglund, C. Lundin, J. Kuusela, P. Roberts, P. J. Br J Cancer Research Article The serum expression of a novel tumour marker, CA 242, defined by monoclonal antibody C 242, was studied in 179 patients with pancreatic cancer. The results were compared with CA 19-9, CA 50 and CEA. CA 242 is a carbohydrate closely related, but not identical, to CA 19-9 and CA 50. The overall sensitivity of the CA 242 assay was 74%: 55% in stage I, 83% in stage II-III and 78% in stage IV disease. The specificity calculated from 112 patients with benign diseases was 91%. CA 19-9 had a higher sensitivity of 83%, but the specificity was only 81%. When comparing the markers by receiver operating characteristic analysis, the sensitivities were almost identical at all specificity levels. The CA 242 level was elevated in 7%, 15% and 7% of patients with benign pancreatic, biliary and liver disease respectively. The corresponding figures for CA 19-9 were 19%, 28% and 15% respectively. The sensitivity of CA 242 was higher than that of CA 50 and CEA at all specificity levels. In conclusion, tumour marker CA 242 seems to be a useful diagnostic tool for the diagnosis of pancreatic cancer, and is an alternative to CA 19-9. The advantage of CA 242 over CA 19-9 is its higher specificity when using the recommended cut-off levels of the assays. Nature Publishing Group 1994-09 /pmc/articles/PMC2033366/ /pubmed/8080735 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Haglund, C.
Lundin, J.
Kuusela, P.
Roberts, P. J.
CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
title CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
title_full CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
title_fullStr CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
title_full_unstemmed CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
title_short CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA.
title_sort ca 242, a new tumour marker for pancreatic cancer: a comparison with ca 19-9, ca 50 and cea.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033366/
https://www.ncbi.nlm.nih.gov/pubmed/8080735
work_keys_str_mv AT haglundc ca242anewtumourmarkerforpancreaticcanceracomparisonwithca199ca50andcea
AT lundinj ca242anewtumourmarkerforpancreaticcanceracomparisonwithca199ca50andcea
AT kuuselap ca242anewtumourmarkerforpancreaticcanceracomparisonwithca199ca50andcea
AT robertspj ca242anewtumourmarkerforpancreaticcanceracomparisonwithca199ca50andcea